Medication info

Rosuvastatin Calcium Tablet 20mg

Prescription medicationTabletExpired
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Alpha Pharma Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
28 tablets (14 tablets/PTP X 2) - 14 tablets/PTP, 28 tablets (14 tablets/PTP X 2) - 2 PTPs/box
Approval status
Expired

MFDS item code 201903276 · Approved 2019.05.21

This product's status changed to Expired on 2024.05.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) Safety and efficacy have not been established in children under 10 years of age.

Ingredients

Manufacturer
Alpha Pharma Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • atypical familial hypercholesterolemia
  • primary dysbeta-lipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of premature coronary heart disease
View approved original text

This medication is used as an adjunct in patients with primary hypercholesterolemia and mixed dyslipidemia who are not adequately controlled by diet and exercise. It is particularly effective in patients with familial hypercholesterolemia, lowering total cholesterol and LDL-cholesterol levels and delaying the progression of atherosclerosis. It may also be prescribed as an adjunct to diet in pediatric patients aged 10 to under 17 years who meet specific criteria. Additionally, it is beneficial for patients with primary dysbeta-lipoproteinemia. In middle-aged and older patients at high risk for cardiovascular disease, it is used to reduce the risk of stroke, myocardial infarction, and arterial revascularization. Thus, this medication is effectively used for various dyslipidemias and the reduction of cardiovascular disease risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) Safety and efficacy have not been established in children under 10 years of age.

Precautions

This medication should not be administered to certain patients. For example, patients with allergies to the ingredients of this medication, patients with severe liver dysfunction, those with muscle diseases, and those with severe kidney diseases should not take it. Women who are pregnant or breastfeeding, or fertile women not using appropriate contraception should not use this medication. Additionally, high-dose administration is prohibited in patients at high risk for muscle-related side effects. This medication contains lactose, so patients with lactose intolerance or related genetic diseases should not take it. It is important to periodically check liver function and muscle status while taking this medication. Patients who consume large amounts of alcohol or have a history of liver disease should exercise extra caution, and patients with hypothyroidism or nephrotic syndrome should treat their underlying conditions before taking this medication. If symptoms such as muscle pain, muscle weakness, or cramps occur, the physician should be informed immediately, and in severe cases, discontinuation of the medication may be necessary. Patients at high risk for severe muscle disease or rhabdomyolysis should have muscle enzyme levels tested before and during treatment. If sudden, severe muscle pain, weakness, or fever occurs while taking this medication, consult healthcare personnel immediately. This medication may interact with some drugs, so if you are taking other medications, it is essential to inform your doctor or pharmacist. Care should be taken, especially when taking it with certain antiviral medications, immunosuppressants, antibiotics, or fibrate classes, as the risk of muscle side effects may increase. If pregnant or breastfeeding, this medication should not be used as safety has not been established, and women who may become pregnant should use appropriate contraceptive methods. In case of overdose, as there is no specific antidote, treatment according to symptoms and tests for liver function and muscle enzymes is necessary. This medication does not significantly affect the ability to drive or operate machinery, but caution is advised due to the possibility of dizziness. Finally, if severe skin reactions, liver dysfunction, or significant muscle abnormalities occur while taking this medication, discontinuation should be immediate, and consultation with healthcare personnel is necessary.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, severe myasthenia gravis, cough, dyspnea, diarrhea, oculobulbar weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), drug-induced lichenoid dermatitis, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, and it is best kept at room temperature between 1 and 30 degrees Celsius. By storing it this way, the efficacy can be maintained, and degradation can be prevented.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

28 tablets (14 tablets/PTP X 2) - 14 tablets/PTP, 28 tablets (14 tablets/PTP X 2) - 2 PTPs/box

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.